Conserved human effector Treg cell transcriptomic and epigenetic signature in arthritic joint inflammation

Mijnheer, Gerdien; Lutter, Lisanne; Mokry, Michal; van der Wal, Marlot; Scholman, Rianne; Fleskens, Veerle; Pandit, Aridaman; Tao, Weiyang; Wekking, Mark; Vervoort, Stephin; Roberts, Ceri; Petrelli, Alessandra; Peeters, Janneke G. C.; Knijff, Marthe; de Roock, Sytze; Vastert, Sebastiaan; Taams, Leonie S.; van Loosdregt, Jorg; van Wijk, Femke

doi:10.1038/s41467-021-22975-7

Download PDF

Article
Open access
Published: 11 May 2021

Conserved human effector Treg cell transcriptomic and epigenetic signature in arthritic joint inflammation

Nature Communications volume 12, Article number: 2710 (2021) Cite this article

9725 Accesses
39 Citations
1 Altmetric
Metrics details

Subjects

Abstract

Treg cells are critical regulators of immune homeostasis, and environment-driven Treg cell differentiation into effector (e)Treg cells is crucial for optimal functioning. However, human Treg cell programming in inflammation is unclear. Here, we combine transcriptional and epigenetic profiling to identify a human eTreg cell signature. Inflammation-derived functional Treg cells have a transcriptional profile characterized by upregulation of both a core Treg cell (FOXP3, CTLA4, TIGIT) and effector program (GITR, BLIMP-1, BATF). We identify a specific human eTreg cell signature that includes the vitamin D receptor (VDR) as a predicted regulator in eTreg cell differentiation. H3K27ac/H3K4me1 occupancy indicates an altered (super-)enhancer landscape, including enrichment of the VDR and BATF binding motifs. The Treg cell profile has striking overlap with tumor-infiltrating Treg cells. Our data demonstrate that human inflammation-derived Treg cells acquire a conserved and specific eTreg cell profile guided by epigenetic changes, and fine-tuned by environment-specific adaptations.

Single cell analysis of spondyloarthritis regulatory T cells identifies distinct synovial gene expression patterns and clonal fates

Article Open access 14 December 2021

TCF1–LEF1 co-expression identifies a multipotent progenitor cell (TH2-MPP) across human allergic diseases

Article 08 April 2024

Direct tissue-sensing reprograms TLR4+ Tfh-like cells inflammatory profile in the joints of rheumatoid arthritis patients

Article Open access 27 September 2021

Introduction

Forkhead box P3-expressing (FOXP3⁺) Treg cells are key players to control aberrant immune responses. Mutations in the FOXP3 gene lead to severe autoimmunity and inflammation in both mice and humans^1,2. Because of their potential for clinical applications, Treg cells have been intensively studied over the last decades.

There is accumulating evidence from mouse models that specific environments such as inflammation or non-lymphoid tissues can induce further differentiation/adaptation into specialized activated Treg cell subsets, also referred to as effector (e)Treg cells^3,4 (reviewed in ref. ⁵). Characteristic for eTreg cells appears to be the maintenance of FOXP3 expression, increased expression of several molecules related to their function such as ICOS, CTLA4, and TIGIT, and adaptation to the local environment. For example, recent studies in mice show that in visceral adipose tissue Treg cells play a dominant role in metabolic homeostasis⁶, whereas Treg cells in skin and gut can promote wound repair and are involved in local stem cell maintenance^7,8.

In mice, eTreg cells have been demonstrated to be crucial in specific inflammatory settings. Interestingly, inflammatory signals can induce the stable upregulation of typical Th cell transcription factors such as T-bet, allowing the Treg cells to migrate to the site of inflammation⁹. Moreover, co-expression of T-bet and Foxp3 is essential to prevent severe Th1 autoimmunity¹⁰. Studies using transgenic mice have contributed to the knowledge in this field, but how this can be translated to humans remains to be elucidated. Because of the interest in the use of Treg cells for therapeutic purposes in a variety of human diseases it is relevant to gain insight in human eTreg cell programming in inflammatory settings.

Also in humans, there is evidence of environment-induced adaptation of human (e)Treg cells^4,7,11 (reviewed in ref. ¹²) including tumor-infiltrating Treg cell signatures^13,14,15. Pertinent issues that remain to be addressed are how diverse and stable human eTreg cell programming is in the inflammatory environment, and whether this is regulated at an epigenetic level.

In this work, we investigate the gene expression profile and active enhancer landscape of human Treg cells in a human autoimmune-associated inflammatory environment. We show that in an inflammatory setting Treg cells differentiate into eTreg and become adapted to the environment both on a transcriptomic and epigenetic level. Furthermore, we demonstrate that there is substantial overlap between the synovial fluid (SF) Treg cell signature and recently published human tumor-infiltrating Treg cell signatures. These findings indicate that human eTreg cell programming is epigenetically imprinted and may be commonly induced in inflammatory conditions ranging from autoimmune to tumor settings.

Results

Enhanced core Treg cell signature in inflamed joints

To investigate whether the gene expression profile of human Treg cells in an inflammatory environment is different from circulating human Treg cells, CD3⁺CD4⁺CD25⁺CD127^low Treg cells and CD3⁺CD4⁺CD25⁻CD127⁺ non-Treg cells were isolated from: synovial exudate obtained from inflamed joints of juvenile idiopathic arthritis (JIA) patients, peripheral blood (PB) from JIA patients with active and inactive disease, and PB from healthy children and healthy adults (Supplementary Fig. 1a for gating strategy). More than 90% of the sorted Treg cell populations were FOXP3 positive (Supplementary Fig. 1b). The transcriptional landscape was determined with RNA-sequencing. An unsupervised principal component analysis (PCA) was performed to study the variability between Treg cells derived from different environments. SF-derived Treg cells clearly clustered separately from PB-derived Treg cells (Fig. 1a), indicating that SF-derived Treg cells have a specific expression pattern compared to PB-derived Treg cells.

**Fig. 1: Distinct profile of human inflammation-derived and peripheral Treg cells.**

In accordance with previous publications we confirmed that SF-derived Treg cells were functional using an in vitro suppression assay (Fig. 1b and Supplementary Fig. 2a)^16,17. As expected, Treg cell signature genes were significantly enriched in SF Treg cells compared to SF CD4⁺ non-Treg cells (Fig. 1c, left panel). Treg cell signature genes were also enriched in SF compared to PB Treg cells derived from both healthy children and JIA patients (Fig. 1c, right panel and Supplementary Fig. 2b). These included Treg cell hallmark genes important for Treg cell stability and function such as FOXP3, CTLA4, and TIGIT, at both the transcriptional and protein level (Fig. 1d, e and Supplementary Figs. 1a and 2c)^18,19. In humans, CD3⁺CD4⁺ non-Treg cells can upregulate FOXP3 and associated markers that as such can serve as markers for T cell activation³. We indeed observed a slight upregulation of FOXP3, CTLA4, and TIGIT at mRNA and protein level in SF non-Treg cells but not near the levels observed in SF Treg cells (Fig. 1d, e and Supplementary Figs. 1b and 2c), further confirming that SF Treg cells and non-Treg cells are distinct cell populations. Together these data demonstrate that the inflammatory environment reinforces the Treg cell-associated program.

Inflammation-derived Treg cells have a specific effector profile

A pairwise comparison between SF- and PB-derived Treg cells from healthy children revealed many differentially expressed genes, including core Treg cell markers including FOXP3 and CTLA4, but also markers that reflect more differentiated Treg cells, like PRDM1 (encoding Blimp-1), ICOS, BATF, and BACH2 (Fig. 2a, Supplementary Data 1). Based on recent literature we analyzed the expression of markers related to eTreg cell differentiation in mice^{3,13,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34}. Hierarchical clustering analysis confirmed that Treg cells clustered separately from non-Treg cells and revealed a cluster of core Treg cell genes with increased expression in all Treg cell groups including CTLA4, FOXP3, IL2RA (encoding CD25), TIGIT, and IKZF2 (encoding Helios) (Fig. 2b, box 1). Furthermore, clustering revealed genes that show molecular heterogeneity within the Treg cell groups. Some markers were expressed almost exclusively by SF Treg cells (including GMZB, ICOS, and IL10) whereas others were highly expressed by SF Treg cells but with shared, albeit lower expression by SF non-Treg cells (including PRDM1, BATF, TNFRSF18 encoding GITR, TNFRSF1B and HAVCR2 encoding TIM-3) (Fig. 2b, box 2). A third cluster concerns genes most highly expressed in non-Treg cells (Fig. 2b, box 3). Some genes in this cluster shared expression with SF Treg cells, such as LAG3, CXCR3, and PDCD1 (encoding PD-1) whereas expression of CD40LG, BACH2, SATB1, CCR7, and TCF7 was clearly lower in SF Treg cells (Fig. 2b, box 2 and 3). Interestingly, the more heterogeneously expressed genes listed in box 2 and 3 were previously associated with an eTreg cell profile, including ICOS, IL10, PRDM1, TNRFSF18, and PDCD1^{3,27,30,31,33}. The increased expression of ICOS, GITR and PD-1 was verified at protein level (Fig. 2c and Supplementary Fig. 3a). Besides the differential expression of these markers, we found a significant enrichment of genes within SF Treg cells recently described in mice to be up- or downregulated in eTreg cells³⁵ (Fig. 2d and Supplementary Fig. 3b), confirming the eTreg cell profile. Collectively, these data demonstrate that autoimmune-inflammation-derived human Treg cells display an eTreg cell signature.

SF Treg cells adapt to the interferon-skewed inflammatory environment

To investigate the relationship between inflammatory environment-derived and PB-derived cells, we performed unsupervised PCA analysis on SF Treg cells and non-Treg cells, and PB Treg cells from healthy children. PB Treg cells were clearly separated from SF-derived cells, confirming that the environment plays a dominant role in determining the transcriptional landscape (Fig. 3a). K-mean clustering analysis showed that SF Treg cells and non-Treg cells share increased expression of genes related to inflammation-associated pathways, including pathways linked to cytokine responses such as Interferon and IL-12 (Supplementary Fig. 4a). K-mean, and subsequent gene ontology analysis of SF Treg cells and all PB Treg cell groups derived from children demonstrated that pathways associated with Th1-skewing were specifically upregulated in SF Treg cells (Fig. 3b and Supplementary Fig. 4b, c). Indeed, expression of the Th1 key transcription factor TBX21 (T-bet), the Th1-related chemokine receptor CXCR3, and IL-12 receptorβ2 (IL12RB2) in SF Treg cells was increased on both mRNA and protein level (Fig. 3c, d and Supplementary Fig. 4d). Expression of TBX21 and CXCR3 was equally high in both SF Treg cells and non-Treg cells, whilst IL12RB2 showed a significantly higher expression in SF Treg cells (adjusted p-value = 6.8E⁻¹⁰). Accordingly, SF Treg cells in contrast to non-Treg cells showed co-expression of T-bet and FOXP3 protein excluding significant contamination of non-Treg cells potentially contributing to the high T-bet levels observed in SF Treg cells (Fig. 3e). These results indicate that SF Treg cells exhibit functional specialization to allow regulation of specific Th cell responses at particular tissue sites, as was previously established in mice^36,37,38. Inline herewith, we found an enrichment in SF Treg cells of the transcriptional signature of TIGIT⁺ Treg cells which have been identified as activated Treg cells selectively suppressing Th1 and Th17 cells in mice¹⁹ (Supplementary Fig. 4e). The higher frequency of memory Treg cells present in SF compared to PB did not explain the differences observed (Supplementary Figs. 2d and e, 3c and 4f).

The high expression of Th1-related proteins raised the question of whether SF Treg cells may have acquired a Th1 phenotype. However, SF Treg cells failed to produce both IL-2 and IFNγ (Fig. 3f and Supplementary Fig. 4g) and responded dose-dependently to IL-2 with increasing pSTAT5 levels (Supplementary Fig. 4h), a signaling pathway pivotal for Treg cell survival and function³⁹. In fact, compared to PB Treg cells, SF Treg cells appeared to be even more responsive to IL-2. Altogether, our findings demonstrate adaptation of SF Treg cells to their inflammatory environment while maintaining Treg cell key features.

Regulation of effector Treg cells by the (super-)enhancer landscape

To explore the mechanistic regulation of the inflammation-adapted eTreg cell profile we analyzed the enhancer landscape of SF Treg cells. Enhancers are distal regulatory elements in the DNA that allow binding of transcription factors and as such coordinate gene expression. Epigenetic regulation of enhancers is critical for context-specific gene regulation⁴⁰. Enhancers can be defined by areas enriched for monomethylation of lysine 4 on histone H3 (H3K4me1 enrichment) and acetylation of lysine 27 on histone H3 (H3K27ac enrichment), where H3K27ac identifies active enhancers⁴¹. ChIP-seq performed for H3K27ac and H3K4me1 using SF Treg cells and healthy adult PB Treg cells revealed differences in enhancer profile and activity, with 3333 out of 37307 and 970 out of 10991 different peaks called between SF and PB Treg cells for H3K27ac and H3K4me1, respectively (Fig. 4a, Supplementary Fig. 5b, upper panel and Supplementary Data 2). We next assessed if the transcriptome of SF Treg cells is reflected at an epigenetic level. Genes that demonstrated increased H3K27ac and/or H3K4me1 were increased at the mRNA level and vice versa (Fig. 4a, Supplementary Fig. 5b, middle and lowest panel and Supplementary Data 2), confirming that gene expression and chromatin-acetylation and -monomethylation are interconnected in these cells.

**Fig. 4: Environment-specific effector Treg cell profile is regulated by the (super-)enhancer landscape.**

Super-enhancers are large clusters of enhancers that specifically regulate genes defining cell identity, both in health and disease^42,43. Super-enhancer-associated genes were identified as the nearest TSS to the center of the enhancer and super-enhancer locus using the ROSE algorithm. Also at super-enhancer level, we found significant enrichment in the transcribed genes, again indicating that the SF Treg cell profile is mediated by epigenetic changes (Fig. 4b and Supplementary Fig. 5c, middle and lowest panel). The analysis of differential super-enhancer-associated genes revealed 337 out of 791 and 317 out of 713 different gene loci for H3K27ac and H3K4me1, respectively (Fig. 4b and Supplementary Fig. 5c, upper panel). Specifically, we identified that super-enhancers associated with genes related to canonical Th1 differentiation, such as TBX21 and IL12RB2, are increased in SF Treg cells (Fig. 4c) demonstrating epigenetic regulation of the environment-associated profile. Core Treg cell genes encoding the effector molecules ICOS, IL10, CTLA4, TNFRSF18, and PDCD1 were associated with increased super-enhancers as well as FURIN and ID2 which are more putative functional Treg cell markers. eTreg cell differentiation was also reflected in the enhancer profile of SF Treg cells, with differential expression of super-enhancer-associated transcriptional regulators including BATF, BACH2, SATB1, TRAF3, and SOCS1. Moreover, we found super-enhancers associated with markers not previously related to (e)Treg cell differentiation and mostly specific for human Treg cells, including VDR (encoding the vitamin D receptor), RXRA (encoding Retinoic acid receptor RXR-alpha), KAT2B (encoding p300/CBP-associated factor (PCAF)), TOX2 (encoding TOX High Mobility Group Box Family Member 2) and IL12RB2^{3,4,6,44,45,46,47,48,49,50,51,52,53}. Inflammation-related homing markers (CCR2, CCR5, CCR7) were associated with differential H3K27ac levels in SF Treg cells as well. Finally, regulation of cell cycling and apoptosis was also mirrored in the super-enhancer landscape of SF compared to PB Treg cells by increased activity of DPH5, MICAL2, PHLDA1, and CCND2. Altogether, these super-enhancer-associated genes reflect adaptation and specialization of Treg cells within an inflammatory environment.

Motif analysis for in silico prediction of transcription factor binding sites in (super-)enhancers specifically upregulated in SF compared to PB Treg cells revealed motifs for Treg cell-specific transcription factors. These included STAT5 and Myb; the latter recently described as a core transcription factor in eTreg cell differentiation⁵³. Recent papers further demonstrated BATF and RelA as crucial regulators for eTreg cells in mice^47,49. In support hereof, we found significant enrichment of BATF, TF65 (encoding RelA), and VDR motifs within the (super-)enhancer regions specifically upregulated in SF Treg cells (Fig. 4d and Supplementary Fig. 5d), thereby further strengthening the eTreg cell profile of SF Treg cells. The most prevalent motifs belong to the activator protein 1 (AP-1) transcription factor subfamily, part of the basic leucine zipper (bZIP) family (Supplementary Fig. 5d) indicating this subfamily is crucial in driving the eTreg cell signature, as similarly proposed by DiSpirito et al.⁵⁴ for pan-tissue Treg cells. Moreover, within the super-enhancers of both the transcriptional regulators VDR and BATF the binding sites for each of them were found, indicating that BATF (in complex with other proteins) and VDR regulate their own gene expression, and also control other eTreg cell genes (Fig. 4e). Together, these observations demonstrate that the inflammation-adapted effector phenotype of SF Treg cells observed on transcriptomic level is reflected at an epigenetic level, with a super-enhancer profile and enrichment of binding sites for eTreg cell genes, showing shared features with other Treg cells in chronically inflamed tissues.

Regulation of eTreg cell differentiation by the vitamin D3 receptor

To extract key gene regulators, based on human transcription factors and co-factors, in the differentiation from healthy PB to SF Treg cells a data-driven network and enrichment approach was performed (RegEnrich). A network of regulators and its targets was constructed (Fig. 5a) with the top predicted regulators driving the differentiation from PB to SF Treg cells were found to be TCF7, LEF1, JUN, SPEN (negative) and ENO1, THRAP3, and VDR (positive) (Fig. 5a, b). SPEN, THRAP3, and VDR have not been previously associated with eTreg cell differentiation. VDR associated downstream with core Treg cell genes including FOXP3 and STAT3, but also Tbx21 (Fig. 5a, c and Supplementary Data 3). In line herewith, there was a strong positive correlation for both FOXP3 (r = 0.772, p < 0.0001) and T-bet (r = 0.937, p < 0.0001) with VDR protein expression (Fig. 5d) reinforcing the predicted regulator network.

**Fig. 5: The vitamin D receptor is a predicted regulator of effector Treg cell differentiation.**

To investigate the direct effect of vitamin D₃ on driving Treg cells towards an effector profile we incubated sorted CD3/CD28-stimulated PB Treg cells with vitamin D₃ (calcitriol/1,25-dihydroxyvitaminD3) and assessed the expression of (e)Treg cell function-related genes. Upon incubation with vitamin D₃ (10 nM; the physiological vitamin D₃ level), increased expression of IL2RA, CTLA4, TNFRSF8 (CD30), and IL10, as well as the eTreg cell transcription factors TBX21 and IRF4 was observed (Fig. 5e). On protein level, CD25, CTLA4, and TNFRSF8 were also significantly increased upon vitamin D₃ incubation (Fig. 5f). In addition, in concordance with the epigenetic data, vitamin D₃ stimulation evoked a positive feedback loop on VDR expression (Fig. 5e). These findings support the hypothesis that vitamin D₃ signaling via VDR contributes to eTreg cell differentiation, while also being positively associated with core Treg cell marker expression.

Similar eTreg cell profile in other inflammatory and tumor environments

To investigate whether the program identified in SF Treg cells is more general for human Treg cells exposed to inflammation, we compared our findings with Treg cells derived from PB and inflammatory joints of rheumatoid arthritis (RA) patients. Indeed, also in Treg cells from the inflammatory exudate of RA patients similar eTreg cell genes were upregulated (Fig. 6a).

**Fig. 6: The effector Treg cell and human tumor Treg cell signature overlap.**

We then compared our data to recently published human tumor-infiltrating Treg cell-specific signatures^13,14,15. Strikingly, the tumor-infiltrating Treg cell signature from De Simone et al. was enriched in SF Treg cells (normalized enrichment score (NES) 1.27, FDR statistical value (FDRq) 0.071; Fig. 6b). Vice versa, the differentially expressed genes in SF Treg cells versus PB Treg cells were enriched in tumor-infiltrating compared to normal tissue Treg cells (Plitas et al., 2016: NES 1.69, FDRq 0.017, Magnuson et al., 2018: NES 1.88, FDRq 0.002; Supplementary Fig. 6a, b). Hierarchical clustering analysis of the tumor-infiltrating gene signature from De Simone et al. further revealed separate clustering of SF Treg cells (Fig. 6c), indicating that the high expression of the signature genes is specific for human Treg cells at a site that is characterized with infiltration of immune cells. We also observed a small set of genes that were not upregulated in SF Treg cells, e.g. CX3CR1, IL17REL, IL1RL1, and IL1RL2, implying environment-restricted adaptation (Fig. 6c). The three genes that were described as the most enriched and distinctive genes in tumor-infiltrating Treg cells, LAYN, MAGEH1, and CCR8, were selectively and highly upregulated in SF Treg cells (Fig. 6d). These data demonstrate that the Treg cell profile we observed is not restricted to the SF exudate from JIA and RA patients. In fact, it likely represents a more global profile of human Treg cells in inflammatory settings, likely fine-tuned by environment-specific adaptations.

To investigate which cues might be specific for SF we explored the differences between upregulated genes in SF and tumor-infiltrating Treg cells. Relatively few pronounced SF-specific genes were found. On gene level, cytotoxic markers including GZMM, GZMA, and GNLY, related to effector cell cytolysis and self-induced apoptosis of Treg cells⁵⁵ were SF-specific (Supplementary Fig. 6c). Gene ontology biological process analysis further revealed that in SF both active cell cycling and apoptotic pathways were upregulated, whereas in the tumor microenvironment cell activation and effector responses were prominent (Supplementary Fig. 6d). In addition, tumor-infiltrating Treg cells showed distinct expression of chemokines and chemokine receptors, e.g., IL-8 (CXCL8), CX3CR1, CXCR7, and CCR10 (Supplementary Fig. 6c), some of which have been proposed as a prognostic marker and/or therapeutic target in cancer⁵⁶.

From the JIA, RA, and tumor datasets we could deduce a set of genes that appear universally upregulated in eTreg cells, and also being reflected in the (super-)enhancer landscape of SF Treg cells (Fig. 6e). ICOS, BATF, MAF, TNFRSF18, and SRGN were revealed as core markers previously also related to mouse eTreg cells. In addition, IL12RB2, VDR, and KAT2B, were identified as core genes, as well as PFKFB3 and LDHA involved in glycolysis and the apoptosis-related genes MICAL2 and TOX2. The latter two have so far not been linked to Treg cells in human or mice, although both have independently been linked to human cancers^57,58. Indeed, gene set enrichment and leading-edge analyses of activated, (shared) tissue, inflammatory and tumor-infiltrating Treg cell gene sets amongst others revealed sharing of the core eTreg cell genes, including BATF, CCND2, CCR8, TNFRSF18, and VDR, (Supplementary Data 4). Even though SF Treg cells are highly activated, there was no enrichment for exhaustion nor exTreg cell-associated genes. Collectively, our results demonstrate that human Treg cells in different inflammatory settings share an effector profile and strongly indicate that inflammation drives eTreg cell differentiation in a comparable manner in different environments.

Discussion

The discovery of eTreg cells in non-lymphoid tissues and inflammatory sites in mice have raised questions how human eTreg cells are transcriptionally and epigenetically programmed in different settings. The present study provides evidence that human Treg cells in a local inflammatory setting undergo further differentiation into specialized eTreg cells. This is reflected by the high expression of TBX21 and CXCR3 and core Treg cell markers including FOXP3, CTLA4, and TIGIT. Essential Treg cell features are maintained, such as suppressive function, IL-2 responsiveness, and absence of cytokine production. The transcriptional changes were mirrored at an epigenetic level, both in the enhancer and super-enhancer landscape, demonstrating that the profile is highly regulated. In addition, we identify previously unappreciated and specific markers in human eTreg cells, like VDR, IL12Rβ2, and BATF; with VDR as a predicted key-regulator in human eTreg cell differentiation. In vitro, vitamin D₃ incubation strengthened the core (e)Treg cell signature at both the protein and mRNA level. Finally, we demonstrate that the profile is not limited to autoimmune inflammation in JIA and RA, but shares almost complete overlap with tumor-infiltrating Treg cells. The similarity between a tumor and an autoimmune setting might seem counterintuitive, since the former reflects an immune-suppressive environment whereas the latter is associated with immune activation. Both environments however share features including immune cell infiltration and inflammation⁵⁹. This overlapping profile might therefore represent a more universal profile of human Treg cells in inflammatory environments. Because of the extensive genome-wide changes of Treg cells from an inflammatory environment insight in their functionality is important. In line with previous reports^16,17, we show that SF Treg cells are indeed suppressive and additionally highly responsive to IL-2 by phosphorylation of STAT5, excluding impaired IL-2 signaling^60,61. This advocates against an intrinsic defect of Treg cells in inflammation. Maintenance of inflammation may be explained by the resistance of local effector cells, previously demonstrated in both JIA and RA^17,62,63.

In mice, functional specialization of Treg cells towards Th1 inflammation by upregulation of T-bet is described as essential to prevent Th1 autoimmunity^9,10. The remarkable co-expression of T-bet and FOXP3 in SF Treg cells in our study, with T-bet levels as high as in SF non-Treg cells, implies that functional specialization is translatable to a human setting. The increased expression of migration markers such as CXCR3 and CCR5 on protein, transcriptional, and enhancer levels further strengthens this, as high T-bet expression is crucial for migration and thus co-localization of Th1-specific Treg cells and Th1 effector T cells via upregulation of these chemokine receptors^9,10.

Contamination of Treg cells with non-Treg cells can be a concern when sorting ex vivo human cells. However, we exclude substantial contamination because (1) our data show robust transcriptomic differences between SF Treg cells and non-Treg cells, with increased expression of Treg cell hallmark genes in SF Treg cells, (2) sorted Treg cells s are > 90% FOXP3⁺, (3) there is clear co-expression of FOXP3 and T-bet on the single-cell level, (4) we show that SF Treg cells, while expressing high T-bet levels, lack cytokine production, potentially caused by high expression of FOXP3, SOCS1, EGR2, and EGR3 (Supplementary Data 1)^64,65. Nevertheless, as recently shown by Miragaia et al.⁴ there may be heterogeneity within the eTreg cell population.

Our study investigated both the transcriptional and epigenetic regulation of eTreg cells in human inflammatory settings allowing us to discern human-specific eTreg cell regulation as well as commonalities between mice and humans. The findings on epigenetic level should still be demonstrated experimentally since although regions marked by H3K27ac/H3K4me1 are associated with active enhancers this is not prima facie evidence of enhancer function^41,66. Furthermore, we have identified (super-)enhancer associated genes as the nearest TSS to the center of the enhancer and super-enhancer locus. It is therefore possible that these (super-)enhancers can regulate other genes than predicted by our analyses⁴¹. This requires further studies into the spatial chromatin organization in Treg cells, especially under inflammatory conditions. The epigenetic landscape of human Treg cells is little explored, with only two papers studying H3K27acetylation and H3K4monomethylation of circulating human Treg cells^67,68. Arvey et al. conclude that the majority of Treg cell lineage-specific elements are not conserved between mice and human further emphasizing the lack of knowledge of the human Treg cell epigenetic landscape. Gao et al. focused on SNPs within enhancers of PB Treg cells from Type 1 diabetes patients, and in line with our data showed, that cell cycle and apoptosis regulation is highly reflected in the enhancer landscape of these patients. These data further underscore the need for additional studies, especially in non-lymphoid tissues during non-homeostatic conditions. We found similarities between mice and humans in eTreg cell differentiation regarding downregulation of SATB1, BACH2, TCF7, and LEF1, all associated with a super-enhancer in PB but not SF Treg cells. Although all four genes are crucial for Treg cell development, recent reports show that downregulation of these regulators is necessary for further differentiation of Treg cells and preventing conversion into Th cells^{44,52,69,70,71,72,73}. BACH2 can transcriptionally repress PRDM1 (encoding Blimp-1) in T cells⁷², and in line herewith we observed increased acetylation and gene expression of PRDM1 in SF Treg cells. This was further supported by the decrease in TCF7 and LEF1, both negatively correlating with eTreg cell marker expression including PRDM1⁷³. Moreover, we found BATF as a prominent marker in SF Treg cells, with increased expression on both transcriptional and epigenetic level, and a binding site in upregulated super-enhancer associated genes. In addition, high BATF expression was also observed in RA SF Treg cells and tumor-infiltrating Treg cells, suggesting BATF is a key transcriptional regulator in both human and mice eTreg cells. We also found remarkable differences in eTreg cell signature markers compared to what is known from mice. Most pronounced is upregulation of IL12RB2 at both the transcriptional and epigenetic level, and a binding site in upregulated super-enhancer associated genes, whereas in mice eTreg cells this marker is downregulated. Instead, impaired IL-12Rβ2 expression has been reported as a key checkpoint preventing Treg cells from fully differentiating towards Th1 cells in mice³⁸. However, our data are in line with recent reports showing selective expression of IL12RB2 in human PB Treg cells^30,67, suggesting this marker has different functions in human and mice.

Another unexpected finding is the upregulation of VDR in both JIA and RA SF Treg cells, on both transcriptional and epigenetic level, as well as in tumor-infiltrating Treg cells. Although not highlighted, high VDR levels were present in breast tumor-infiltrating Treg cells¹⁴ and uterine eTreg cells⁷⁴. Besides the well-known tolerogenic effects of vitamin D₃⁷⁵, VDR is not well-studied in the Treg cell context, especially in humans. A recent study did show that memory CCR6⁺ Th cells gained a suppressive phenotype, including CTLA4 expression, and functional suppressive capacity similar to Treg cells upon incubation with vitamin D₃⁷⁶. Here we show VDR is a predicted key-regulator in SF eTreg cells, positively correlated with both FOXP3 and T-bet expression.

Another difference is the absence of KLRG1 upregulation in human eTreg cells. In mice, KLRG1 is a key marker to identify eTreg cells, although not crucial for eTreg cell function⁷⁷. KLRG1 is not upregulated on SF Treg cells and associated with a super-enhancer only in PB Treg cells. In addition, in our data gene expression of KLRG1 is restricted to non-Treg cells (both SF and PB). Confusing the findings are discrepancies possibly caused by the tissue measured or comparison made. Miragaia et al.⁴ showed upregulation of PIM1 in non-lymphoid Treg cells compared to PB Treg cells in mice, but PIM1 was not expressed in human tissue Treg cells. In our data however, PIM1 is highly increased in SF compared to PB Treg cells of healthy adults and children (Supplementary Data 1). In summary, we show that human eTreg cells show similarities in eTreg cell differentiation markers identified in mice, but also found human-specific eTreg cell markers including IL-12Rβ2 and VDR, and absence of KLRG1.

Previous research has shown that ex vivo human Treg cells are highly glycolytic⁷⁸, in line with their high proliferative capacity⁷⁹. In mice increased glycolysis is required for eTreg cell differentiation and migration to inflammatory sites^80,81. In support hereof, glycolysis-associated genes including PFKFB3, LDHA, and PKM2 were increased in SF Treg cells on both RNA and (super-)enhancer levels. Finally, ENO1, encoding the glycolytic enzyme Enolase 1, is a predicted key-regulator of eTreg cell differentiation.

Lately, the application of Treg cell-based therapies for autoimmune diseases and transplantation settings is gaining renewed interest. Promising data from animal models and clinical trials, both with cell therapy involving the adoptive transfer and with low dose IL-2 administration, pave the way for Treg cell therapies to reach the clinic⁸². Our data show that circulating human Treg cells are markedly different from their counterparts derived from sites characterized by immune activation. This is reflected in the expression of effector markers and transcriptional regulators, but also in the expression of specific chemokine receptors. Regarding Treg cell-based therapies appreciating that specific environments may require adapted Treg cells, both for migration and function, is important. Moreover, in this study, we profiled human eTreg cells abundantly present at sites of inflammation. This information can form a basis for follow-up studies that may eventually allow the characterization of small amounts of circulating eTreg cells, for example to monitor patients undergoing treatment.

In conclusion, our study uncovered the transcriptional and epigenetic program that defines human inflammatory Treg cells. SF Treg cells display an environment-adapted as well as an eTreg cell phenotype established at the epigenetic level. Moreover, we describe striking similarities of the eTreg cell program with tumor-infiltrating Treg cells and SF Treg cells from RA patients. This revealed a set of genes shared with human eTreg cells from affected sites in JIA, RA, and cancer including BATF, VDR, MICAL2, TOX2, KAT2B, PFKFB3, and IL12Rβ2. Finally, we show that THRAP3, ENO1, and VDR are predicted key-regulators driving human SF eTreg cell differentiation at the transcriptomic level.

Methods

Collection of SF and PB Samples

Patients with JIA (n = 41) were enrolled by the Pediatric Rheumatology Department at University Medical Center of Utrecht (The Netherlands). Of the JIA patients n = 8 were diagnosed with extended oligo JIA and n = 33 with oligo JIA, according to the revised criteria for JIA⁸³, with an average age of 11.3 years (range 3.2–19 years) and disease duration at the time of inclusion of 4.9 years (range 0.1–15 years). Active disease was defined by physician global assessment of ≥1 active joint (swelling, limitation of movement), and inactive disease was defined as the absence hereof. Additional parameters including the Juvenile Arthritis Disease Activity Score (JADAS), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were also taken into account. Patients with RA (n = 7) were enrolled by the rheumatology outpatient clinic at Guy’s and St. Thomas’ Hospital NHS Trust (United Kingdom). The average age of RA patients was 61 years (range 30–75 years). PB and SF was obtained when patients visit the outpatient clinic via vein puncture or intravenous drip, and by therapeutic joint aspiration of the affected joints, respectively. The study was conducted in accordance with the Institutional Review Board of the University Medical Center Utrecht (approval no. 11-499/C; JIA) and the Bromley Research Ethics Committee (approval no. 06/Q0705/20; RA). PB from healthy adult volunteers (HC, n = 20, average age 41.7 years with range 27–62 years) was obtained from the Mini Donor Service at University Medical Center Utrecht. PB from n = 8 healthy children (average age 11.4 years with range 7.3–15.6 years; approval no. 05-149/K) was obtained from a cohort of control subjects for a case-control clinical study. Informed consent was obtained from all the participants and/or from their parents/guardians/legally authorized representatives.

Isolation of SFMC and PBMC

SF of JIA patients was incubated with hyaluronidase (Sigma-Aldrich) for 30 min at 37 °C to break down hyaluronic acid. SF mononuclear cells (SFMCs) and peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll Isopaque density gradient centrifugation (GE Healthcare Bio-Sciences, AB) and were used after freezing in fetal calf serum (FCS) (Invitrogen) containing 10% DMSO (Sigma-Aldrich).

Suppression assay

CD3⁺CD4⁺CD25⁺CD127^low cells (Treg cells) were isolated from frozen PBMC (see Supplementary Fig. 1a for gating strategy), using the FACS Aria III (BD). Antibodies used for sorting are: anti-human CD3-BV510 (clone OKT3, 1:400), CD25-PE/Cy7 (clone M-A251, 1:25; BD), CD127-AF647 (clone HCD127, 1:50; Biolegend), CD4-FITC (clone RPA-T4, 1:200; eBioscience). To check for FOXP3 expression of the sorted populations cells were fixed and permeabilized by using eBioscience Fixation and Permeabilization buffers (Invitrogen) and stained with anti-human FOXP3-eF450 (clone PCH101, 1:50; eBioscience) (see Supplementary Fig. 1b). Read out of proliferation is performed with the following antibodies: CD3-PerCP/Cy5.5 (clone UCHT1, 1:100; Biolegend), CD4-FITC (clone RPA-T4, 1:200; eBioscience), CD8-APC (clone SK1, 1:100; BD). Total PBMC were labeled with 2 µM ctViolet (Thermo Fisher Scientific) and cultured alone or with different ratios of sorted Treg cells (1:16, 1:8, 1:4, 1:2). Cells were cultured in RPMI1640 media containing 10% human AB serum with the addition of L-Glutamine and Penicillin/Streptomycin. PBMC were stimulated by 0,1 µg/ml coated anti-CD3 (eBioscience) and incubated for four days in a 96 well round bottom plate (Nunc) at 37 °C. After 4 days cells were stained with CD3, CD4, and CD8 for read out of proliferation by flow cytometry performed on FACS Canto II (BD Biosciences) and data were analyzed using FlowJo Software v10 (Tree Star Inc.).

Cell phenotyping

PBMC and SFMC were thawed and stained by surface and intranuclear/cellular staining with the following antibodies: CD3 BV510 (clone OKT3, 1:400), CD3 AF700 (clone UCHT1, 1:50), CD127 PerCP-Cy5.5 (clone HCD127, 1:25), CD127 PE-Cy7 (clone HCD127, 1:50), CXCR3 FITC (clone G025H7, 1:40), IL2 PB (clone MQ1-17H12, 1:100; Biolegend), CD4 APC-eFluor780 (clone RPA-T4, 1:50), FOXP3 APC (clone PCH101, 1:25), TIGIT PerCP-eFluor710 (clone MBSA43, 1:50), FOXP3 eF450 (clone PCH101, 1:50), ICOS APC (clone ISA3, 1:20; eBioscience), CD127 BV421 (clone HIL-7R-M21, 1:40), CD25 PE/Cy7 (clone MA251, 1:25), CTLA4 PE (clone BNI3, 1:12.5), PD-1 BV711 (clone EH12.1, 1:100), IL12Rβ2 PE (clone 2B6/12β2, 1:5), T-bet PE-CF594 (clone 04-46, 1:25), IFNγ PerCP-Cy5.5 (clone 4S.B3, 1:40), FOXP3 PE-CF594 (clone 259D/C7, 1:50; BD), GITR FITC (clone #110416, 1:8.3; R&D). For measurement of cytokines thawed cells were stimulated with 20 ng/mL PMA (MP Biomedicals) and 1 µg/mL ionomycin (Calbiochem) in RPMI supplemented with 10% AB. After 30 min incubation at 37 °C Golgi stop (BD Biosciences) was added followed by 3.5 h of incubation at 37 °C. For intranuclear/cellular staining the Intracellular Fixation & Permeabilization Buffer Set (eBioscience) was used. See Supplementary Fig. 1a and c for gating strategy of FOXP3⁺ Treg cells and non-Treg cells, and Supplementary Figs. 2–4 for MFI plots of the markers of interest. Data acquisition was performed on a BD LSRFortessa (BD Biosciences) and analysis as above.

STAT5 Phosflow

PBMC and SFMC were thawed and resuspended in PBS (0.5–1.0 × 10⁶ living cells/tube). Surface staining of CD3-BV510 (clone OKT3, 1:400, Biolegend) and CD4-FITC (clone RPA-T4, 1:200, eBioscience) was performed for 25 min at 4 °C. Cells were then stimulated with 0, 1, 10 or 100 IU/ml human (h)IL-2 (Proleukin; Novartis) for 30 min at 37 °C, fixated and permeabilized by using buffers from the Transcription Factor Phospho Buffer Set (BD Biosciences). Intranuclear staining of FOXP3-eF450 (clone PCH101, 1:50), T-bet-eF660 (clone eBio4B10, 1:50; eBioscience), CD25-PE/CY7 (clone M-A251, 1:25) and pSTAT5-PE (clone pY695, 1:25; BD) was performed for 50 min at 4 °C. See Supplementary Fig. 1a and c for gating strategy of FOXP3⁺ Treg cells and non-Treg cells, and Supplementary Fig. 4h for the gating of pSTAT5. Data acquisition and analysis as above.

RNA-sequencing

CD3⁺CD4⁺CD25⁺CD127^low and CD3⁺CD4⁺CD25⁻CD127⁺ cells were sorted by flow cytometry from HC PBMC and JIA patient SFMC and PBMC (see Supplementary Fig. 1a for gating strategy). Total RNA was extracted using the AllPrep DNA/RNA/miRNA Universal Kit (Qiagen) as specified by the manufacturer’s instructions and stored at −80 °C. Sequencing libraries were prepared using the Rapid Directional RNA-Seq Kit (NEXTflex). Libraries were sequenced using the Nextseq500 platform (Illumina), producing single end reads of 75 bp (Utrecht Sequencing Facility). Sequencing reads were mapped against the reference human genome (hg19, NCBI37) using BWA (v0.7.5a, mem –t 7 –c 100 –M -R) (see Supplementary Data 5 for quality control information). Differential gene expression was performed using DEseq2 (v1.2). For K-means clustering and PCA analysis, genes with fold change between samples on 10th and 90th quantile at least 1 log2 RPKM and expression at least 2 log2 RPKM in the sample with the maximal expression were used. K-means clustering was done on gene expression medians per group, with an empirically chosen k of 14. The scripts used for analysis are available at⁸⁴. Gene Ontology pathway analyses were performed using ToppFun (https://toppgene.cchmc.org/enrichment.jsp) with input genes belonging to the defined k-mean clusters, with an FDR-corrected p-value < 0.05 defining significance. Gene set enrichment analysis (GSEA, v3.0, and v4.0.3)⁸⁵, with as input the log2 RPKM data, was used to assess whether specific signatures were significantly enriched in one of the subsets. One thousand random permutations of the phenotypic subgroups were used to establish a null distribution of enrichment score against which a NES and FDR-corrected q values were calculated. Gene-sets were either obtained by analyzing raw data using GEO2R (NCBI tool) or downloaded from published papers, or self-made based on the H3K27ac/H3K4me1 data. In particular, the following published gene data sets were used: human core Treg cell signature: Ferraro et al.³¹; effector Treg cell signature in mice: Dias et al.⁵³; tumor-infiltrating Treg cell signature: De Simone et al.¹³. Plitas et al.¹⁴. Magnuson et al.¹⁵; effector Treg cell genes in mice: Levine et al.³⁵; TIGIT⁺ Treg cell signature in mice: Joller et al.¹⁹. Identification of key-regulators was performed using RegEnrich⁸⁶ v1.0.0 based on the differential gene expression data followed by unsupervised WGCNA for the network inference, mean RPKM counts >0 were included, and Fisher’s exact test was used for enrichment analysis. Heatmaps and subsequent hierarchical clustering analyses using One minus Pearson correlation were performed using Morpheus software (v0.1.1.1, https://software.broadinstitute.org/morpheus/).

H3K27ac and H3K4me1 ChIP-sequencing

PBMC from HC and SFMC from JIA patients were thawed and 0.5–1 million CD3⁺CD4⁺CD25⁺CD127^low cells were sorted by flow cytometry (see Supplementary Fig. 1a for gating strategy). For each sample, cells were crosslinked with 2% formaldehyde and crosslinking was stopped by adding 0.2 M glycine. Nuclei were isolated in 50 mM Tris (pH 7.5), 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, and 1% Triton X-100 and lysed in 20 mM Tris (pH 7.5), 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.3% SDS. Lysates were sheared using Covaris microTUBE (duty cycle 20%, intensity 3, 200 cycles per burst, 60-s cycle time, eight cycles) and diluted in 20 mM Tris (pH 8.0), 150 mM NaCl, 2 mM EDTA, 1% X-100. Sheared DNA was incubated overnight with anti-histone H3 acetyl K27 antibody (ab4729; Abcam) or anti-histone H3 (mono methyl K4) antibody (ab8895; Abcam) pre-coupled to protein A/G magnetic beads. Cells were washed and crosslinking was reversed by adding 1% SDS, 100 mM NaHCO3, 200 mM NaCl, and 300 µg/ml proteinase K. DNA was purified using ChIP DNA Clean & Concentrator kit (Zymo Research), end-repair, a-tailing, and ligation of sequence adaptors were done using Truseq nano DNA sample preparation kit (Illumina). Samples were PCR amplified, checked for the proper size range and for the absence of adaptor dimers on a 2% agarose gel and barcoded libraries were sequenced 75 bp single-end on Illumina NextSeq500 sequencer (Utrecht DNA sequencing facility). Sample demultiplexing and read quality assessment was performed using BaseSpace (Illumina) software. Reads with quality score of Q > 30 were used for downstream analysis. Reads were mapped to the reference genome (hg19/hg38) with Bowtie 2.1.0 using default settings for H3K27ac ChIP-seq and BWA for H3K4me1 ChIP-seq (see Supplementary Data 5 for quality control information). SAM files were converted to BAM files using samtools version 0.1.19. Peaks were subsequently called using MACS-2.1.0. Enriched regions were identified compared to the input control using MACS2 callpeak--nomodel --exttsize 300 --gsize=hs -p 1e-9. The mapped reads were extended by 300 bp and converted to TDF files with igvtools-2.3.36 and were visualized with IGV-2.7.2⁸⁷ for H3K27ac and H3K4me1 ChIP-seq. Differential binding analysis was performed using the R package DiffBind v1.8.5. In DiffBind read normalization was performed using the TMM technique using reads mapped to peaks which were background subtracted using the input control. Enhancer gene associations were determined as the nearest TSS to the center of the enhancer and super-enhancer locus. Super-enhancers were identified by employing the ROSE algorithm⁸⁸ using a stitching distance of the MACS2 called peaks of 12.5 kb, peaks were excluded that were fully contained in the region spanning 1000 bp upstream and downstream of an annotated TSS (-t 1000). The H3K27ac/H3K4me1 signal was corrected for background using the input control and subsequently ranked by increasing signal (Fig. S5A). Super-enhancer gene associations were determined as the nearest TSS to the center of the enhancer and super-enhancer locus using the ROSE algorithm. BEDtools v2.17.0 was used for general manipulation of peak bed-files. Motif enrichment analysis was performed using the HOMER software v4.11 (findMotifsGenome.pl; hg19/hg38; -size 200). ChIP-seq data for activated Treg cells, VDR, and BATF were retrieved from GEO:GSE43119 (GSM1056948 and GSM1056952), GSE89431 (GSM2371449) and GSE32465 (GSM803538), respectively.

VDR and 1,25 vitamin D3 incubation assay

Thawed HC PBMC and JIA patient SFMC were stained by surface and intranuclear staining as described above with the following antibodies: anti-human fixable viability dye eF506 (1:1000), FOXP3-PerCP/Cy5.5 (clone PCH101, 1:50; eBioscience), CD3-AF700 (clone UCHT1, 1:50), CD4-BV785 (clone OKT4, 1:100; Biolegend), CD25-BV711 (clone 2A3, 1:50), CD127-BV605 (clone A019D5, 1:50; Sony Biotechnology), and VDR-PE (clone D-6, 1:100; Santa Cruz Biotechnology). In addition, CD4⁺ T cells were isolated from fresh PBMC using the CD4⁺ T cell isolation kit and LS column (Miltenyi Biotec). Sorted Treg cells (CD3⁺CD4⁺CD25⁺CD127^low, 50.000) were plated in a round bottom 96-wells plate in the presence of 10% human AB serum, anti-CD3/CD28 (Dynabeads Human T-activator CD3/CD28, Thermo Fisher Scientific) at a 1:5 ratio (1 bead to 5 cell ratio), 100 IU/ml (h)IL-2 (Proleukin; Novartis) for 2 days. In addition, 0 (control) or 10 nM 1α,25-Dihydroxyvitamin D3 (Sigma-Aldrich) was added. Expanded Treg cells were stained by surface and intranuclear staining as described above with the following antibodies: anti-human fixable viability dye eF506 (1:1000), FOXP3-eF450 (clone PCH101, 1:50; eBioscience), CD3-AF700 (clone UCHT1, 1:50), CD4-APC/Cy7 (clone RPA-T4, 1:100; Biolegend), CD25-BV711 (clone 2A3, 1:50), and CD30-FITC (clone Ber-H8, 1:12.5), and CTLA4-APC (clone BNI3, 1:12.5; BD). See Supplementary Figs. 1–2 for the gating strategy. Data acquisition and analysis as above. Furthermore, total RNA from expanded Treg cells was extracted using the PicoPure RNA Isolation Kit (Thermo Fisher Scientific) and RNA was reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad). Quantitative RT-PCR was performed using SYBR Select Master Mix (Life Technologies) according to the manufacturer’s instructions and measured on a QuantStudio 12k Flex real-time PCR (Thermo Fisher Scientific). Fold change was calculated using the delta-delta Ct method (2^ΔΔCt) normalized to the housekeeping gene GUSB in Microsoft Excel 2016. The primers used are listed in Supplementary Table 1.

Microarray RA Treg cells

CD14⁺ monocytes (purity > 98%) were depleted through positive selection using CD14 MicroBeads (Miltenyi Biotec). CD4⁺ T cells were isolated from the CD14⁻ cell fraction by negative selection (Miltenyi Biotec) and stained with CD4-PerCP/Cy5.5 (clone SK3, 1:200), CD45RA-APC/Cy7 (clone HI100, 1:50), CD45RO-PB (clone UCHL1, 1:50), CD127-FITC (clone A019D5, 1:50; BioLegend), and CD25-PE (clone REA945, 1:50; Miltenyi Biotec). CD4⁺CD45RA⁻CD45RO⁺CD25⁺CD127^low cells (memory Treg cells, see Supplementary Fig. 1a for gating strategy)), were sorted using a BD FACSAria II. Sorted Treg cell samples were lysed in 1000 μl of TRIzol (Invitrogen). Chloroform (200 μl) was added, and the samples were then whirl mixed and incubated for 2–3 min at room temperature. Following centrifugation (10.000 × g for 15 min at 4 °C), the water phase was further purified using the ReliaPrepTM RNA Miniprep system (Promega) per manufacturer’s instructions. RNA integrity was confirmed on an Agilent Technologies 2100 bioanalyzer. One hundred nanograms of total RNA was used to prepare the targets (Affymetrix) in accordance with the manufacturer’s instructions. Hybridization cocktails were hybridized onto a Human Gene 2.0 ST Array. Chips were scanned and gene expression data were normalized using the RMA algorithm. Gene expression analysis was performed using Qlucore Omics Explorer software, version 3.0.

Statistics and reproducibility

For ChIP-seq and RNA-seq analysis, p-values were adjusted with the Benjamini-Hochberg procedure. Protein and cytokine expression was analyzed with Pearson’s correlation, two-tailed Mann–Whitney U test, Two-way ANOVA with Sidak correction for multiple testing or a mixed-effects model with Dunnett post hoc on paired data with missing values using GraphPad Prism. All experimental flow cytometry and sorting data concern two or more independent experiments with similar results. RNA- and ChIP-sequencing runs were performed in one batch.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

RNA-seq and ChIP-seq data generated for this study have been deposited in the Gene Expression Omnibus (GEO) database under the accession codes: GSE161426 and GSE156418. ChIP-seq data for activated Treg cells, VDR and BATF was retrieved from GEO:GSE43119 (GSM1056948 and GSM1056952), GSE89431 (GSM2371449) and GSE32465] (GSM803538), respectively. Raw data for figures are provided in the Source Data file. All other data are available in the manuscript and its Supplementary information.

Code availability

The code used for RNA-seq analysis are available at https://github.com/mmokry/Mijnheer_Nat_Commun_2021⁸⁴.

References

Brunkow, M. E. et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27, 68–73 (2001).
Article CAS PubMed Google Scholar
Ochs, H. D. et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27, 20–21 (2001).
Article PubMed CAS Google Scholar
Cretney, E. et al. The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells. Nat. Immunol. 12, 304–311 (2011).
Article CAS PubMed Google Scholar
Miragaia, R. J. et al. Single-cell transcriptomics of regulatory T cells reveals trajectories of tissue adaptation. Immunity 50, 493–504.e7 (2019).
Article CAS PubMed PubMed Central Google Scholar
Liston, A. & Gray, D. H. D. Homeostatic control of regulatory T cell diversity. Nat. Rev. Immunol. 14, 154–165 (2014).
Article CAS PubMed Google Scholar
Vasanthakumar, A. et al. The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue–resident regulatory T cells. Nat. Immunol. 16, 276–285 (2015).
Article CAS PubMed Google Scholar
Povoleri, G. A. M. et al. Human retinoic acid–regulated CD161 + regulatory T cells support wound repair in intestinal mucosa. Nat. Immunol. 19, 1403–1414 (2018).
Article CAS PubMed PubMed Central Google Scholar
Kalekar, L. A. et al. Regulatory T cells in skin are uniquely poised to suppress profibrotic immune responses. Sci. Immunol. 4, aaw2910 (2019).
Article CAS Google Scholar
Koch, M. A. et al. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat. Immunol. 10, 595–602 (2009).
Article CAS PubMed PubMed Central Google Scholar
Levine, A. G. et al. Stability and function of regulatory T cells expressing the transcription factor T-bet. Nature 546, 421–425 (2017).
Article ADS CAS PubMed PubMed Central Google Scholar
Miyara, M. et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30, 899–911 (2009).
Article CAS PubMed Google Scholar
Panduro, M., Benoist, C. & Mathis, D. Tissue Tregs. Annu. Rev. Immunol. 34, 609–633 (2016).
Article CAS PubMed PubMed Central Google Scholar
De Simone, M. et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity 45, 1135–1147 (2016).
Article PubMed PubMed Central CAS Google Scholar
Plitas, G. et al. Regulatory T cells exhibit distinct features in human breast cancer. Immunity 45, 1122–1134 (2016).
Article CAS PubMed PubMed Central Google Scholar
Magnuson, A. M. et al. Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types. Proc. Natl Acad. Sci. USA 115, E10672–E10681 (2018).
Article CAS PubMed PubMed Central Google Scholar
Van Amelsfort, J. M. R., Jacobs, K. M. G., Bijlsma, J. W. J., Lafeber, F. P. J. G. & Taams, L. S. CD4+CD25+ regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum. 50, 2775–2785 (2004).
Article PubMed Google Scholar
Wehrens, E. J. et al. Functional human regulatory T cells fail to control autoimmune inflammation due to PKB/c-akt hyperactivation in effector cells. Blood 118, 3538–3548 (2011).
Article CAS PubMed Google Scholar
Teh, P. P., Vasanthakumar, A. & Kallies, A. In Progress in Molecular Biology and Translational Science (ed. Liston, A.) 155–174 (ScienceDirect, 2015).
Joller, N. et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 40, 569–581 (2014).
Article CAS PubMed PubMed Central Google Scholar
Shalev, I. et al. Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis. J. Immunol. 180, 249–260 (2008).
Article CAS PubMed Google Scholar
Ye, L. et al. TCR usage, gene expression and function of two distinct FOXP3(+)Treg subsets within CD4(+)CD25(hi) T cells identified by expression of CD39 and CD45RO. Immunol. Cell Biol. 94, 293–305 (2016).
Article CAS PubMed Google Scholar
Do, J.-S. et al. An IL-27/Lag3 axis enhances Foxp3+ regulatory T cell-suppressive function and therapeutic efficacy. Mucosal Immunol. 9, 137–145 (2016).
Article CAS PubMed Google Scholar
Okubo, Y., Mera, T., Wang, L. & Faustman, D. L. Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2. Sci. Rep. 3, 3153 (2013).
Article ADS PubMed PubMed Central Google Scholar
Wang, R. et al. Expression of GARP selectively identifies activated human FOXP3+regulatory T cells. Proc. Natl Acad. Sci. USA106, 13439–13444 (2009).
Article ADS CAS PubMed PubMed Central Google Scholar
Bin Dhuban, K. et al. Coexpression of TIGIT and FCRL3 identifies Helios+ human memory regulatory T cells. J. Immunol. 194, 3687–3696 (2015).
Article CAS Google Scholar
Fu, G. et al. Themis controls thymocyte selection through regulation of T cell antigen receptor-mediated signaling. Nat. Immunol. 10, 848–856 (2009).
Article CAS PubMed PubMed Central Google Scholar
Ito, T. et al. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 28, 870–880 (2008).
Article CAS PubMed PubMed Central Google Scholar
Müller, M., Herrath, J. & Malmström, V. IL-1R1 is expressed on both Helios(+) and Helios(−) FoxP3(+) CD4(+) T cells in the rheumatic joint. Clin. Exp. Immunol. 182, 90–100 (2015).
Article PubMed PubMed Central CAS Google Scholar
Pan, F. et al. Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science 325, 1142–1146 (2009).
Article ADS CAS PubMed PubMed Central Google Scholar
Bhairavabhotla, R. et al. Transcriptome profiling of human FoxP3(+) regulatory T cells. Hum. Immunol. 77, 201–213 (2015).
Article PubMed PubMed Central CAS Google Scholar
Ferraro, A. et al. Interindividual variation in human T regulatory cells. Proc. Natl Acad. Sci. USA 111, E1111–E1120 (2014).
Article CAS PubMed PubMed Central Google Scholar
Miyazaki, M. et al. Id2 and Id3 maintain the regulatory T cell pool to suppress inflammatory disease. Nat. Immunol. 15, 767–776 (2014).
Article CAS PubMed PubMed Central Google Scholar
Mason, G. M. et al. Phenotypic complexity of the human regulatory T cell compartment revealed by mass cytometry. J. Immunol. 195, 2030–2037 (2015).
Article CAS PubMed Google Scholar
Cheng, G. et al. IL-2 receptor signaling is essential for the development of Klrg1+ terminally differentiated T regulatory cells. J. Immunol. 189, 1780–1791 (2012).
Article CAS PubMed Google Scholar
Levine, A. G., Arvey, A., Jin, W. & Rudensky, A. Y. Continuous requirement for the TCR in regulatory T cell function. Nat. Immunol. 15, 1070–1078 (2014).
Article CAS PubMed PubMed Central Google Scholar
Chaudhry, A. et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326, 986–991 (2009).
Article ADS CAS PubMed PubMed Central Google Scholar
Zheng, Y. et al. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature 458, 351–356 (2009).
Article ADS CAS PubMed PubMed Central Google Scholar
Koch, M. A. et al. T-bet+ Treg cells undergo abortive Th1 cell differentiation due to impaired expression of IL-12 receptor β2. Immunity 37, 501–510 (2012).
Article CAS PubMed PubMed Central Google Scholar
Chinen, T. et al. An essential role for the IL-2 receptor in Treg cell function. Nat. Immunol. 17, 1322–1333 (2016).
Article CAS PubMed PubMed Central Google Scholar
Heintzman, N. D. et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459, 108–112 (2009).
Article ADS CAS PubMed PubMed Central Google Scholar
Creyghton, M. P. et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl Acad. Sci. USA 107, 21931–21936 (2010).
Article ADS CAS PubMed PubMed Central Google Scholar
Hnisz, D. et al. XSuper-enhancers in the control of cell identity and disease. Cell 155, 934–947 (2013).
Article CAS PubMed Google Scholar
Hu, Z. & Tee, W.-W. Enhancers and chromatin structures: regulatory hubs in gene expression and diseases. Biosci. Rep. 37, BSR20160183 (2017).
Article CAS PubMed PubMed Central Google Scholar
Yang, B.-H. et al. TCF1 and LEF1 control Treg competitive survival and Tfr development to prevent autoimmune diseases. Cell Rep. 27, 3629–3645.e6 (2019).
Article CAS PubMed PubMed Central Google Scholar
DiSpirito, J. R. et al. Molecular diversification of regulatory T cells in nonlymphoid tissues. Sci. Immunol. 3, eaat5861 (2018).
Koizumi, S. et al. JunB regulates homeostasis and suppressive functions of effector regulatory T cells. Nat. Commun. 9, 5344 (2018).
Article ADS CAS PubMed PubMed Central Google Scholar
Hayatsu, N. et al. Analyses of a mutant Foxp3 allele reveal BATF as a critical transcription factor in the differentiation and accumulation of tissue regulatory T cells. Immunity 47, 268–283.e9 (2017).
Article CAS PubMed Google Scholar
Vaeth, M. et al. Tissue resident and follicular Treg cell differentiation is regulated by CRAC channels. Nat. Commun. 10, 1183 (2019).
Article ADS PubMed PubMed Central CAS Google Scholar
Delacher, M. et al. Genome-wide DNA-methylation landscape defines specialization of regulatory T cells in tissues. Nat. Immunol. 18, 1160–1172 (2017).
Article CAS PubMed PubMed Central Google Scholar
Sullivan, J. M., Höllbacher, B. & Campbell, D. J. Cutting Edge: dynamic expression of Id3 defines the stepwise differentiation of tissue-resident regulatory T cells. J. Immunol. https://doi.org/10.4049/jimmunol.1800917 (2018).
Alvisi, G. et al. IRF4 instructs effector Treg differentiation and immune suppression in human cancer. J. Clin. Invest. 130, 3137–3150 (2020).
Article CAS PubMed PubMed Central Google Scholar
Roychoudhuri, R. et al. BACH2 represses effector programs to stabilize Treg-mediated immune homeostasis. Nature 498, 506–510 (2013).
Article ADS CAS PubMed PubMed Central Google Scholar
Dias, S. et al. Effector regulatory T cell differentiation and immune homeostasis depend on the transcription factor Myb. Immunity 46, 78–91 (2017).
Article CAS PubMed Google Scholar
DiSpirito, J. R. et al. Molecular diversification of regulatory T cells in nonlymphoid tissues. Sci. Immunol. 3, eaat5861 (2018).
Article PubMed PubMed Central Google Scholar
Sula Karreci, E. et al. Human regulatory T cells undergo self-inflicted damage via granzyme pathways upon activation. JCI insight 2, e91599 (2017).
Article PubMed Central Google Scholar
Loyher, P.-L., Rodero, M. P., Combadière, C. & Boissonnas, A. In Cancer Immunology: A Translational Medicine Context (ed. Rezaei, N.) 235–262 (Springer International Publishing, 2020).
Tessema, M. et al. Differential epigenetic regulation of TOX subfamily high mobility group box genes in lung and breast cancers. PLoS ONE 7, e34850 (2012).
Article ADS CAS PubMed PubMed Central Google Scholar
Mariotti, S. et al. MICAL2 is a novel human cancer gene controlling mesenchymal to epithelial transition involved in cancer growth and invasion. Oncotarget 7, 1808–1825 (2016).
Article PubMed Google Scholar
Elinav, E. et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer 13, 759–771 (2013).
Article CAS PubMed Google Scholar
Verbsky, J. W. & Chatila, T. A. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders. Curr. Opin. Pediatr. 25, 708–714 (2013).
Article CAS PubMed PubMed Central Google Scholar
Parackova, Z. et al. T regulatory lymphocytes in type 1 diabetes: Impaired CD25 expression and IL-2 induced STAT5 phosphorylation in pediatric patients. Autoimmunity 49, 523–531 (2016).
Article CAS PubMed Google Scholar
Herrath, J. et al. The inflammatory milieu in the rheumatic joint reduces regulatory T-cell function. Eur. J. Immunol. 41, 2279–2290 (2011).
Article CAS PubMed Google Scholar
Petrelli, A. et al. Self-sustained resistance to suppression of CD8+ Teff cells at the site of autoimmune inflammation can be reversed by tumor necrosis factor and interferon-γ blockade. Arthritis Rheumatol. 68, 229–236 (2016).
Article CAS PubMed Google Scholar
Singh, R. et al. Egr2 and 3 inhibit T-bet–mediated IFN-γ production in T cells. J. Immunol. 198, 4394–4402 (2017).
Article CAS PubMed PubMed Central Google Scholar
Takahashi, R., Nakatsukasa, H., Shiozawa, S. & Yoshimura, A. SOCS1 Is a key molecule that prevents regulatory T cell plasticity under inflammatory conditions. J. Immunol. 199, 149–158 (2017).
Article CAS PubMed Google Scholar
Wong, L., Jiang, K., Chen, Y. & Jarvis, J. N. Genetic insights into juvenile idiopathic arthritis derived from deep whole genome sequencing. Sci. Rep. 7, 2657 (2017).
Article ADS PubMed PubMed Central CAS Google Scholar
Arvey, A. et al. Genetic and epigenetic variation in the lineage specification of regulatory T cells. Elife 4, e07571 (2015).
Article PubMed PubMed Central Google Scholar
Gao, P. et al. Risk variants disrupting enhancers of TH1 and TREG cells in type 1 diabetes. Proc. Natl Acad. Sci. USA 116, 7581–7590 (2019).
Article CAS PubMed PubMed Central Google Scholar
Beyer, M. et al. Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat. Immunol. 12, 898–907 (2011).
Article CAS PubMed PubMed Central Google Scholar
Vahedi, G. et al. Super-enhancers delineate disease-associated regulatory nodes in T cells. Nature 520, 558–562 (2015).
Article ADS CAS PubMed PubMed Central Google Scholar
Kitagawa, Y. et al. Guidance of regulatory T cell development by Satb1-dependent super-enhancer establishment. Nat. Immunol. 18, 173–183 (2017).
Article CAS PubMed Google Scholar
Afzali, B. et al. BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency. Nat. Immunol. 18, 813–823 (2017).
Article CAS PubMed PubMed Central Google Scholar
Xing, S. et al. Tcf1 and Lef1 are required for the immunosuppressive function of regulatory T cells. J. Exp. Med. 216, 847–866 (2019).
Article CAS PubMed PubMed Central Google Scholar
Wienke, J. et al. Human Tregs at the materno-fetal interface show site-specific adaptation reminiscent of tumor Tregs. JCI Insight 5, e137926 (2020).
Article PubMed Central Google Scholar
Bscheider, M. & Butcher, E. C. Vitamin D immunoregulation through dendritic cells. Immunology 148, 227–236 (2016).
Article CAS PubMed PubMed Central Google Scholar
Dankers, W. et al. Human memory Th17 cell populations change into anti-inflammatory cells with regulatory capacity upon exposure to active vitamin D. Front. Immunol. 10, 1504 (2019).
Article CAS PubMed PubMed Central Google Scholar
Meinicke, H. et al. KLRG1 impairs regulatory T-cell competitive fitness in the gut. Immunology 152, 65–73 (2017).
Article CAS PubMed PubMed Central Google Scholar
Procaccini, C. et al. The proteomic landscape of human ex vivo regulatory and conventional T cells reveals specific metabolic requirements. Immunity 44, 406–421 (2016).
Article CAS PubMed PubMed Central Google Scholar
Vukmanovic-Stejic, M. et al. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J. Clin. Invest. 116, 2423–2433 (2006).
Article CAS PubMed PubMed Central Google Scholar
Sun, I.-H. et al. mTOR complex 1 signaling regulates the generation and function of central and effector Foxp3 + regulatory T cells. J. Immunol. 201, 481–492 (2018).
Article CAS PubMed Google Scholar
Kishore, M. et al. Regulatory T cell migration is dependent on glucokinase-mediated glycolysis. Immunity 47, 875–889.e10 (2017).
Article CAS PubMed PubMed Central Google Scholar
Ferreira, L. M. R., Muller, Y. D., Bluestone, J. A. & Tang, Q. Next-generation regulatory T cell therapy. Nat. Rev. Drug Discov. 18, 749–769 (2019).
Article CAS PubMed PubMed Central Google Scholar
Petty, R. E. et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J. Rheumatol. 25, 1991–1994 (1998).
CAS PubMed Google Scholar
Mokry, M. Conserved human effector Treg cell transcriptomic and epigenetic signature in inflammation. Mijnheer_Nat_Commun_2021 https://doi.org/10.5281/zenodo.4615296 (2021).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
Article ADS CAS PubMed PubMed Central Google Scholar
Tao, W., Radstake, T. R. D. J. & Pandit, A. RegEnrich: an R package for gene regulator enrichment analysis reveals key role of ETS transcription factor family in interferon signaling. Preprint at bioRxiv https://doi.org/10.1101/2021.01.24.428029 (2021).
Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24–26 (2011).
Article CAS PubMed PubMed Central Google Scholar
Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307–319 (2013).
Article CAS PubMed PubMed Central Google Scholar
Zheng, C. et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 169, 1342–1356.e16 (2017).
Article CAS PubMed Google Scholar
Borcherding, N. et al. Mapping the immune environment in clear cell renal carcinoma by single-cell genomics. Commun Biol 4, 122 (2021).
Article CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

We would like to thank J. van Velzen and P. Andriessen van der Burght for technical assistance, and Anoushka Samat for help with qPCR primer design. F. van Wijk is supported by a VIDI grant from ZonMw (91714332).

Author information

These authors contributed equally: Gerdien Mijnheer, Lisanne Lutter.
These authors jointly supervised this work: Jorg van Loosdregt, Femke van Wijk.

Authors and Affiliations

Center for Translational Immunology, Pediatric Immunology & Rheumatology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
Gerdien Mijnheer, Lisanne Lutter, Michal Mokry, Marlot van der Wal, Rianne Scholman, Aridaman Pandit, Weiyang Tao, Stephin Vervoort, Alessandra Petrelli, Janneke G. C. Peeters, Marthe Knijff, Sytze de Roock, Sebastiaan Vastert, Jorg van Loosdregt & Femke van Wijk
Regenerative Medicine Center Utrecht, Department of Pediatrics, University Medical Center Utrecht, Utrecht, The Netherlands
Michal Mokry
Epigenomics facility, University Medical Center Utrecht, Utrecht, The Netherlands
Michal Mokry & Mark Wekking
Centre for Inflammation Biology and Cancer Immunology, School of Immunology & Microbial Sciences, King’s College London, London, UK
Veerle Fleskens, Ceri Roberts & Leonie S. Taams
Regenerative Medicine Center Utrecht, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
Stephin Vervoort & Jorg van Loosdregt

Authors

Gerdien Mijnheer
View author publications
You can also search for this author in PubMed Google Scholar
Lisanne Lutter
View author publications
You can also search for this author in PubMed Google Scholar
Michal Mokry
View author publications
You can also search for this author in PubMed Google Scholar
Marlot van der Wal
View author publications
You can also search for this author in PubMed Google Scholar
Rianne Scholman
View author publications
You can also search for this author in PubMed Google Scholar
Veerle Fleskens
View author publications
You can also search for this author in PubMed Google Scholar
Aridaman Pandit
View author publications
You can also search for this author in PubMed Google Scholar
Weiyang Tao
View author publications
You can also search for this author in PubMed Google Scholar
Mark Wekking
View author publications
You can also search for this author in PubMed Google Scholar
Stephin Vervoort
View author publications
You can also search for this author in PubMed Google Scholar
Ceri Roberts
View author publications
You can also search for this author in PubMed Google Scholar
Alessandra Petrelli
View author publications
You can also search for this author in PubMed Google Scholar
Janneke G. C. Peeters
View author publications
You can also search for this author in PubMed Google Scholar
Marthe Knijff
View author publications
You can also search for this author in PubMed Google Scholar
Sytze de Roock
View author publications
You can also search for this author in PubMed Google Scholar
Sebastiaan Vastert
View author publications
You can also search for this author in PubMed Google Scholar
Leonie S. Taams
View author publications
You can also search for this author in PubMed Google Scholar
Jorg van Loosdregt
View author publications
You can also search for this author in PubMed Google Scholar
Femke van Wijk
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: G.M., L.L., Fv.W., and J.v.L. Performed experiments: G.M., L.L. M.v.d.W., R.S., M.K., S. Vervoort, and A. Petrelli, Data analysis: G.M., L.L., M.M., M.v.d.W., J.G.C.P., A. Pandit, W.T., M.W., and J.v.L. Patient selection and clinical interpretation: G.M., L.L., S. Vastert, and S.d.R. Supplied RA dataset: V.F., C.R., and L.S.T. Writing: G.M., L.L., M.v.d.W., J.v.L., and F.v.W. Supervision: J.v.L. and F.v.W. All authors reviewed and edited the manuscript.

Corresponding author

Correspondence to Femke van Wijk.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Peer review information Nature Communications thanks James Jarvis, Naganari Ohkura, Nancy Olsen and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Peer Review File

Description of Additional Supplementary Files

Supplementary Data 1

Supplementary Data 2

Supplementary Data 3

Supplementary Data 4

Supplementary Data 5

Reporting Summary

Source data

Source Data

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Mijnheer, G., Lutter, L., Mokry, M. et al. Conserved human effector Treg cell transcriptomic and epigenetic signature in arthritic joint inflammation. Nat Commun 12, 2710 (2021). https://doi.org/10.1038/s41467-021-22975-7

Download citation

Received: 02 August 2020
Accepted: 08 April 2021
Published: 11 May 2021
DOI: https://doi.org/10.1038/s41467-021-22975-7

This article is cited by

Development of a cellular model to study CCR8 signaling in tumor-infiltrating regulatory T cells
- Libao Liu
- Laurie Rangan
- Tom Van Loy
Cancer Immunology, Immunotherapy (2024)
IL-23 stabilizes an effector Treg cell program in the tumor microenvironment
- Tobias Wertheimer
- Pascale Zwicky
- Burkhard Becher
Nature Immunology (2024)
m6A methyltransferase METTL3 programs CD4+ T-cell activation and effector T-cell differentiation in systemic lupus erythematosus
- Shuang Lu
- Xingyu Wei
- Ming Zhao
Molecular Medicine (2023)
Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment
- Hailong Tian
- Jiangjun Cao
- Canhua Huang
Bone Research (2023)
Electrodes for Li-ion batteries: From high-voltage LiCoO2 to Co-reduced/Co-free layered oxides with potential anodes
- Luting Song
- Weiguo Chu
Nano Research (2023)

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.